LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

TG Therapeutics Inc

Fechado

SetorSaúde

31.93 0.88

Visão Geral

Variação de preço das ações

24h

Atual

Mín

31.23

Máximo

32.19

Indicadores-chave

By Trading Economics

Rendimento

23M

28M

Vendas

20M

141M

P/E

Médio do Setor

85.811

35.664

Margem de lucro

19.97

Funcionários

370

EBITDA

25M

38M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+2.9% upside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

543M

5.1B

Abertura anterior

31.05

Fecho anterior

31.93

Sentimento de Notícias

By Acuity

21%

79%

48 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

TG Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

16 de set. de 2025, 17:03 UTC

Grandes Movimentos do Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 de set. de 2025, 16:49 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

GD Culture Shares Drop After Deal for Pallas Capital

16 de set. de 2025, 16:11 UTC

Grandes Movimentos do Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 de set. de 2025, 23:40 UTC

Conversa de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 de set. de 2025, 23:34 UTC

Conversa de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 de set. de 2025, 23:20 UTC

Conversa de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 de set. de 2025, 21:10 UTC

Aquisições, Fusões, Aquisições de Empresas

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 de set. de 2025, 20:51 UTC

Conversa de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 de set. de 2025, 20:50 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

16 de set. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

16 de set. de 2025, 20:25 UTC

Ganhos

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 de set. de 2025, 20:24 UTC

Ganhos

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 de set. de 2025, 19:19 UTC

Conversa de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 de set. de 2025, 18:52 UTC

Conversa de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 de set. de 2025, 18:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

16 de set. de 2025, 18:44 UTC

Conversa de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 de set. de 2025, 18:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 de set. de 2025, 18:38 UTC

Conversa de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 de set. de 2025, 18:19 UTC

Conversa de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 de set. de 2025, 18:01 UTC

Conversa de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 de set. de 2025, 17:34 UTC

Conversa de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 de set. de 2025, 16:53 UTC

Ganhos

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 de set. de 2025, 16:20 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

16 de set. de 2025, 16:15 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Commodities Roundup: Market Talk

16 de set. de 2025, 16:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Global Energy Roundup: Market Talk

16 de set. de 2025, 16:09 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 de set. de 2025, 15:35 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 de set. de 2025, 15:35 UTC

Conversa de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 de set. de 2025, 15:22 UTC

Conversa de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 de set. de 2025, 15:21 UTC

Conversa de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparação entre Pares

Variação de preço

TG Therapeutics Inc Previsão

Preço-alvo

By TipRanks

2.9% parte superior

Previsão para 12 meses

Média 32.67 USD  2.9%

Máximo 50 USD

Mínimo 11 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para TG Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

3 ratings

1

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 34.86Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

48 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat